|1.||Jarvis, Michael F: 8 articles (08/2012 - 12/2002)|
|2.||McGaraughty, Steve: 5 articles (08/2012 - 12/2002)|
|3.||Honore, Prisca: 4 articles (02/2008 - 12/2002)|
|4.||Xu, Guang-Yin: 3 articles (12/2015 - 01/2015)|
|5.||Jiang, Xinghong: 3 articles (12/2015 - 01/2015)|
|6.||Lee, Chih-Hung: 3 articles (08/2006 - 12/2002)|
|7.||Zhu, Chang Z: 3 articles (09/2005 - 12/2002)|
|8.||Wismer, Carol T: 3 articles (09/2005 - 12/2002)|
|9.||Zhou, You-Lang: 2 articles (12/2015 - 01/2015)|
|10.||Hu, Shufen: 2 articles (12/2015 - 04/2015)|
12/01/2014 - "Additionally, EA was more potent in reducing mechanical allodynia and thermal hyperalgesia when combined with A-317491 through intrathecal administration. "
10/18/2012 - "The mechanical allodynia was reversed by P2X(3)R antagonist, A-317491 administration into whisker pad skin. "
03/01/2011 - "Furthermore, A-317491, a selective P2X(3)/P2X(2/3) receptor antagonist, significantly reversed the hyperalgesia of OVX rats. "
11/03/2004 - "administration of A-317491 dose-dependently reversed mechanical hyperalgesia. "
11/03/2004 - "The effect of A-317491 (5-([(3-Phenoxybenzyl)[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl)-1,2,4-benzenetricarboxylic acid), a recently described selective P2X3 and P2X(2/3) receptor antagonist, on inflammatory mechanical hyperalgesia was examined. "
|2.||Neuralgia (Stump Neuralgia)
07/01/2011 - "The discovery of A-317491 allowed their validation as chronic inflammatory and neuropathic pain targets, but this molecule has a very limited oral bioavailability and CNS penetration. "
01/01/2009 - "Furthermore, the selective P2X3/P2X2/3 antagonist A-317491 inhibited nNOS activation assessed by NO formation in spinal slices prepared from neuropathic pain model mice. "
12/01/2003 - "We have recently reported that systemic delivery of A-317491, the first non-nucleotide antagonist that has high affinity and selectivity for blocking P2X3 homomeric and P2X2/3 heteromeric channels, is antinociceptive in rat models of chronic inflammatory and neuropathic pain. "
08/01/2003 - "More recently, the acute systemic administration of a highly selective non-nucleotide P2X(3) antagonist, A317491, has been shown to fully block specific types of chronic inflammatory and neuropathic pain in animal models in the absence of cardiovascular and CNS side effects associated with other analgesic compounds. "
12/24/2002 - "A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat."
08/01/2006 - "The discovery of A-317491, a selective and potent non-nucleotide P2X(3) antagonist, provided a pharmacological tool to determine the site and mode of action of P2X(3)-containing receptors in different pain behaviours, including neuropathic, inflammatory and visceral pain. "
10/01/2005 - "Furthermore, these studies have also outlined the antinociceptive profile for a P2X(3)/P2X(2/3) receptor antagonist, as A-317491 was effective in models of chronic inflammatory and neuropathic pain, but not in models of acute, acute inflammatory or visceral pain. "
11/01/2012 - "Intrathecal or local injection of A-317491 significantly attenuated pain behaviour induced by bone cancer. "
08/05/2012 - "Thus, systemically administered A-317491 did not demonstrate a robust effect in the present mouse model of cancer-induced bone pain."
08/05/2012 - "Also, acute administration of A-317491 (100 μmol/kgs.c.) had no effect in the progressed stage of the bone cancer pain model. "
06/01/2008 - "These data suggest that A-317491 is effective at improving the signs of CYP-induced cystitis and that the P2X3 or P2X2/3 receptor pathway is involved in bladder overactivity observed during CYP-induced cystitis."
06/01/2008 - "In this study, we investigated the effect of the recently developed P2X3 and P2X2/3 receptor antagonist A-317491 on cyclophosphamide (CYP)-induced cystitis to determine whether a P2X receptor antagonist could be beneficial for the treatment of bladder overactivity induced by CYP. "
06/01/2008 - "Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats."
|5.||Premature Cardiac Complexes (Extrasystoles)
|1.||Purinergic P2X3 Receptors
|3.||2',3'- O- (2,4,6- trinitro- cyclohexadienylidine)adenosine 5'-triphosphate
|4.||Octoxynol (Triton X 100)
|9.||salicylhydroxamic acid (SHAM)
|10.||Suramin (Suramin Sodium)